Cumberland Pharmaceuticals Inc: Form 10-Q for the period ended Jun 30, 2021
Filed with the SEC on Aug 13, 2021 and accepted by EDGAR at Aug 13, 2021, 17:08 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2021-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2021-04-01 to 2021-06-30 | $9.1m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 6 months2021-01-01 to 2021-06-30 | $19.6m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months2021-04-01 to 2021-06-30 | $1.7m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 6 months2021-01-01 to 2021-06-30 | $4.2m | us-gaap:CostOfGoodsAndServicesSold |
| Research and development | 3 months2021-04-01 to 2021-06-30 | $1.4m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2021-01-01 to 2021-06-30 | $2.6m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2021-04-01 to 2021-06-30 | −$1.4m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2021-01-01 to 2021-06-30 | −$1.8m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2021-04-01 to 2021-06-30 | $25.9k | us-gaap:InterestExpense |
| Interest expense | 6 months2021-01-01 to 2021-06-30 | $50.3k | us-gaap:InterestExpense |
| Income tax | 3 months2021-04-01 to 2021-06-30 | $7.5k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months2021-01-01 to 2021-06-30 | $14.9k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2021-04-01 to 2021-06-30 | $1.2m | us-gaap:NetIncomeLoss |
| Net income | 6 months2021-01-01 to 2021-06-30 | $1.4m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2021-04-01 to 2021-06-30 | $0.08 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months2021-01-01 to 2021-06-30 | $0.09 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2021-04-01 to 2021-06-30 | $0.08 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2021-01-01 to 2021-06-30 | $0.09 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2021-04-01 to 2021-06-30 | 15,109,246 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months2021-01-01 to 2021-06-30 | 15,171,589 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months2021-01-01 to 2021-06-30 | $4.5m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2021-01-01 to 2021-06-30 | $34.5k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Share repurchases | 6 months2021-01-01 to 2021-06-30 | $777.7k | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2021-06-30 | $25.7m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2021-06-30 | $46.7m | us-gaap:AssetsCurrent |
| Total assets | At period end2021-06-30 | $88.9m | us-gaap:Assets |
| Current liabilities | At period end2021-06-30 | $18.6m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2021-06-30 | $41.0m | us-gaap:Liabilities |
| Shareholders' equity | At period end2021-06-30 | $48.0m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001628280-21-017022. Last ingested by Listed: Oct 26, 2026, 16:41 ET. Listed shows no prices and gives no investment advice.